Related Experiment Video
Updated: Jan 13, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
32.4K
Outcomes after biologic initiation among patients with severe asthma and normal lung function in the CHRONICLE study
Reynold A Panettieri1, Arjun Mohan2, Njira L Lugogo2
1Rutgers Institute for Translational Medicine and Science, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Respiratory Research
|January 8, 2026
Summary
Biologic treatments effectively reduce exacerbations and emergency department visits in severe asthma patients with normal lung function, similar to those with reduced lung function. This finding improves understanding of severe asthma management.
Area of Science:
- Pulmonology
- Pharmacology
- Real-world evidence studies
Background:
- Severe asthma (SA) affects patients with varying lung function.
- A subset of SA patients exhibit normal pre-bronchodilator lung function (FEV1 ≥80% predicted).
- The efficacy of biologics in SA patients with normal lung function remains under-explored.
Purpose of the Study:
- To assess the effectiveness of biologic treatments in adults with SA and normal lung function.
- To compare treatment outcomes between SA patients with normal versus reduced lung function.
Main Methods:
- Analysis of real-world data from the CHRONICLE study (NCT03373045) in the US.
- Categorization of SA patients into normal (n=67) and reduced (n=166) lung function groups based on pre-BD FEV1.
- Comparison of annualized exacerbation rates and ED visit rates pre- and post-biologic initiation.
Main Results:
- Biologic treatment significantly reduced exacerbation rates by 50% in normal lung function SA and 59% in reduced lung function SA.
- Rates of exacerbation-related ED visits decreased by 44% in normal lung function SA and 63% in reduced lung function SA.
- Biologics demonstrated comparable effectiveness in both patient groups.
Conclusions:
- Biologic therapies are effective in mitigating exacerbations and ED visits for SA patients with normal lung function.
- Treatment outcomes for SA patients with normal lung function are similar to those with reduced lung function when treated with biologics.
- These findings support the use of biologics across the spectrum of lung function in severe asthma.
More Related Videos
Related Concept Videos
01:24Asthma-III: Symptoms and Complications
3.2K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
3.2K
01:20Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
01:30Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
01:26COPD: Management Using Bronchodilators and Corticosteroids
719
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
719
01:26Asthma-II: Pathophysiology and Classification
4.1K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.1K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K